18F-FDG (Fluorodeoxyglucose) is an 18F (fluor-18) labeled radioactive glucose molecule with which the glucose metabolism can be visualized.
With this tracer, mainly tumors and infections can be detected. 18F-FDG is a popular radiopharmaceutical that is widely used in oncological diagnostics.
Recently, we have received our marketing authorization for 18F-FDG (Fludeoxyglucose (18F) RTM 200 MBq/ml, RVG 121074). Now, we are ready for the next step: together with Life Radiopharma delivering 18F-FDG to a wide range of hospitals in the Netherlands and Belgium.
18F-FDOPA (Fluorodopa) is metabolized into the neurotransmitter dopamine after uptake into the brain.
Defects in the dopamine system are related to a variety of neurological disorders such as Parkinson’s disease. 18F-FDOPA (Fluorodopa) is therefore used in neurological diagnostics, but also in the imaging of specific neuro-endocrine tumors.
An important reason for the installation of a cyclotron at the campus of Radboudumc is that it enables the use of short living radionuclides. 13N (nitrogen-13) has a half-life of 10 minutes and can therefore not be obtained from external sources.
[N-13]NH3 is used to quantify the perfusion of the cardiac muscle. Since it is a small molecule, having a high diffusion speed, it can easily reach the capillaries of the heart. This provides valuable diagnostic information in patients with heart complaints that cannot be explained by coronary dysfunction. Previously it was difficult to find the cause of these complaints.
18F-PSMA-1007 is currently under investigation as a potential radiopharmaceutical targeting the prostate-specific membrane antigen (PSMA).
PSMA has considerable overexpression on most prostate cancer cells.
PSMA-PET can be used for diagnosis of prostate cancer, in particular for detection of recurrent disease with low PSA levels.
PSMA-based imaging holds great promise to improve prostate cancer management.
18F -MPPF is a radiotracer that binds to the serotonin 1A receptor in the brain.
Various neurological and psychiatric disorders are related to a disturbance in the serotonergic system in the brain. Medication is often aimed at this system (for instance selective serotonin-reuptake inhibitors for patients with anxiety disorders or depression). 18F -MPPF can help in finding the right treatment (medication) for these patients and contribute to diagnosing, imaging and characterizing serotonin-related diseases.
Due to the short half-life (20 minutes) of 11C (carbon-11), it has to be produced on location.
11C tracers are mainly used in preclinical and clinical PET-studies for the development of new medicines and treatments. Together with Radboudumc’s Department of Nuclear Medicine, Radboud Translational Medicine will set up a research line aimed at the development of new 11C tracers.